180 Life Sciences Corp. (NASDAQ:ATNFW) Sees Large Decline in Short Interest

180 Life Sciences Corp. (NASDAQ:ATNFW) was the recipient of a large decline in short interest during the month of April. As of April 15th, there was short interest totalling 9,000 shares, a decline of 74.9% from the March 31st total of 35,900 shares. Based on an average daily trading volume, of 46,100 shares, the short-interest ratio is presently 0.2 days.

180 Life Sciences Price Performance

Shares of NASDAQ ATNFW remained flat at $0.01 during trading hours on Friday. 9,825 shares of the company traded hands, compared to its average volume of 46,661. 180 Life Sciences has a 1 year low of $0.00 and a 1 year high of $0.02. The firm’s 50 day simple moving average is $0.01 and its two-hundred day simple moving average is $0.01.

180 Life Sciences Company Profile

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor.